Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-22T22:51:21.347Z Has data issue: false hasContentIssue false
  • English
  • Français

REPORT FROM THE CATALAN AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT (CAHTA)

Published online by Cambridge University Press:  01 October 1999

Get access Rights & Permissions [Opens in a new window]

Abstract

Recently, the advent and extension of vancomycin-resistant enterococci (VRE) has raised the awareness of the professional community, given that this antimicrobial is used as first-choice therapy for multiresistant gram-positive bacteria. The objectives are:

Type
TECHNOLOGY ASSESSMENT REPORTS
Information
International Journal of Technology Assessment in Health Care , Volume 15 , Issue 4 , October 1999 , pp. 767 - 769
Copyright
© 1999 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)